Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter

References

• Naftolin F, Schneider H PG, Sturdee D W, for the Executive Committee of the International Menopause Society. Guidelines for hormone treatment of women in the menopausal transition and beyond. Climacteric 2004; 7: 333–337
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Genazzani A R. The missing R. Gynecol Endocrinol 2003; 17: 91–94
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995; 38: 199–210
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M J, Manson J E, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Herrington D M, Reboussin D M, Brosnihan K B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–529
   PubMed Web of Science ®Google Scholar
• Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women. Effects on cognitive function and dementia. JAMA 1998; 279: 688–695
   PubMed Web of Science ®Google Scholar
• Shumaker S A, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA 2004; 291: 2947–2958
   PubMed Web of Science ®Google Scholar
• Pines A. Compliance with hormone therapy after Women's Health Initiative: who is to blame?. Menopause 2005; 12: 363–365
   PubMed Web of Science ®Google Scholar
• Mikkola T S, Clarkson T B, Notelovitz M. Postmenopausal hormone therapy before and after the Women's Health Initiative study: what consequences?. Ann Med 2004; 36: 402–413
   PubMed Web of Science ®Google Scholar
• Garbe E, Suissa S. Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy and acute coronary outcomes: methodological issues between randomized and observational studies. Hum Reprod 2004; 19: 8–13
   PubMed Web of Science ®Google Scholar
• Skouby S O, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51: 8–14
   PubMed Web of Science ®Google Scholar
• Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004; 11: 589–600
   PubMed Web of Science ®Google Scholar
• Posición Latinoamericana en relación con el estado actual de la terapia hormonal. Ginecol Obstet Mex 2005; 73: 205–211
   PubMedGoogle Scholar
• Hilditch J R, Chen S, Norton P G, Lewis J. Experience of menopausal symptoms by Chinese and Canadian women. Climacteric 1999; 2: 164–173
   PubMedGoogle Scholar
• Obermeyer C M. Menopause across cultures: a review of the evidence. Menopause 2000; 7: 184–192
   PubMed Web of Science ®Google Scholar
• Gold E B, Sternfeld B, Kelsey J L, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol 2000; 152: 463–473
   PubMed Web of Science ®Google Scholar
• Avis N E, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001; 52: 345–356
   PubMed Web of Science ®Google Scholar
• Fu S -Y, Anderson D, Courtney M. Cross-cultural menopausal experience: comparison of Australian and Taiwanese women. Nurs Health Sci 2003; 5: 77–84
   PubMedGoogle Scholar
• Tan D, Haines C J, Limpaphayom K K, Holinka C F, Ausmanas M K. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) Study. Maturitas 2005; 52: 35–51
   PubMed Web of Science ®Google Scholar
• Haines C J, Xing S -M, Park K -H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 264–276
   PubMed Web of Science ®Google Scholar
• Salkind N J. Exploring Research, 4th edn. Prentice Hall, Upper Saddle River, NJ 2000; 132–133
   Google Scholar
• Zhao G, Wang L, Yan R, Dennerstein L. Menopausal symptoms: experience of Chinese women. Climacteric 2000; 3: 135–144
   PubMedGoogle Scholar
• Punyahotra S, Dennerstein L, Lehert P. Menopausal experiences of Thai women. 1: Symptoms and their correlates. Maturitas 1997; 26: 1–7
   PubMed Web of Science ®Google Scholar
• Limpaphayom K K, Taechakraichana N, Jaisamrarn U, et al. Prevalence of osteopenia and osteoporosis in Thai women. Menopause 2001; 8: 64–69
   Google Scholar